Perspective Therapeutics Stock Performance
| CATX Stock | 2.62 0.11 4.38% |
The company holds a Beta of 0.2, which implies not very significant fluctuations relative to the market. As returns on the market increase, Perspective Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Perspective Therapeutics is expected to be smaller as well. At this point, Perspective Therapeutics has a negative expected return of -0.68%. Please make sure to check Perspective Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Perspective Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Perspective Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 4.38 | Five Day Return (6.76) | Year To Date Return (6.09) | Ten Year Return (57.74) | All Time Return (94.86) |
Last Split Factor 1:10 | Last Split Date 2024-06-17 |
1 | Brokerages Set Perspective Therapeutics, Inc. Price Target at 11.89 | 11/18/2025 |
2 | UBS lowers Perspective Therapeutics stock price target on competition concerns - Investing.com Nigeria | 11/21/2025 |
3 | Perspective Therapeutics Coverage Initiated by Analysts at Truist Financial - MarketBeat | 11/25/2025 |
4 | Perspective Therapeutics Inc Stock Analysis and Forecast - Stock Split Announcements Fast Growing Trading Plans - earlytimes.in | 12/15/2025 |
5 | Aug Decliners How Perspective Therapeutics Inc AAJ0 stock benefits from digital adoption - 2025 Stock Rankings Daily Stock Trend Watchlist - moha.gov.vn | 12/26/2025 |
6 | Denison Reports Readiness to Commence Construction of Flagship Phoenix ISR Project and Provides Capital Cost Update | 01/02/2026 |
7 | 43 Bn Airborne ISR Markets, 2020-2025, 2025-2030F, 2035F - Growing Counterterrorism Efforts and Geopolitical Tensions Further Drive Market Growth | 01/09/2026 |
8 | Space-Based C4ISR Global Research Report 2026 4.49 Bn Market Trends, Competitive Landscape, Strategies, and Opportunities, 2020-2025, 2025-2030F, 2035F | 01/14/2026 |
| Begin Period Cash Flow | 9.4 M | |
| Total Cashflows From Investing Activities | -218.9 M |
Perspective | Build AI portfolio with Perspective Stock |
Perspective Therapeutics Relative Risk vs. Return Landscape
If you would invest 449.00 in Perspective Therapeutics on October 17, 2025 and sell it today you would lose (187.00) from holding Perspective Therapeutics or give up 41.65% of portfolio value over 90 days. Perspective Therapeutics is currently does not generate positive expected returns and assumes 6.0708% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Perspective, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Perspective Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Perspective Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Perspective Therapeutics, and traders can use it to determine the average amount a Perspective Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.112
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CATX |
Based on monthly moving average Perspective Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Perspective Therapeutics by adding Perspective Therapeutics to a well-diversified portfolio.
Perspective Therapeutics Fundamentals Growth
Perspective Stock prices reflect investors' perceptions of the future prospects and financial health of Perspective Therapeutics, and Perspective Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Perspective Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (133.31) % | ||||
| Current Valuation | 15.76 M | ||||
| Shares Outstanding | 74.34 M | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 173.57 X | ||||
| Gross Profit | (60.89 M) | ||||
| EBITDA | 10.46 M | ||||
| Net Income | (79.28 M) | ||||
| Total Debt | 4.06 M | ||||
| Book Value Per Share | 3.26 X | ||||
| Cash Flow From Operations | (18.29 M) | ||||
| Earnings Per Share | (1.51) X | ||||
| Market Capitalization | 186.59 M | ||||
| Total Asset | 341.1 M | ||||
| Retained Earnings | (231.72 M) | ||||
| Working Capital | 212.93 M | ||||
About Perspective Therapeutics Performance
Evaluating Perspective Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Perspective Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Perspective Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 84.62 | 88.85 | |
| Return On Tangible Assets | (0.31) | (0.30) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.27) | (0.25) | |
| Return On Equity | (0.31) | (0.33) |
Things to note about Perspective Therapeutics performance evaluation
Checking the ongoing alerts about Perspective Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Perspective Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Perspective Therapeutics generated a negative expected return over the last 90 days | |
| Perspective Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (79.28 M) with loss before overhead, payroll, taxes, and interest of (60.89 M). | |
| Perspective Therapeutics generates negative cash flow from operations | |
| About 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: New release Ballot When Fate Called Their Name tells a tale of youth, loyalty, and the hidden cost of war |
- Analyzing Perspective Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Perspective Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Perspective Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Perspective Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Perspective Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Perspective Therapeutics' stock. These opinions can provide insight into Perspective Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.